To study the level of and changes in basal metabolic rate (BMR) in children with a solid tumour at diagnosis and during treatment in order to provide a more accurate estimate of energy requirements for nutritional support. Design: An observational study. Setting: Tertiary care at the Centre for Paediatric Oncology, University Hospital Nijmegen. Subjects: Thirteen patients were recruited from a population of patients visiting the University Hospital Nijmegen for treatment. All patients asked to participate took part in and completed the study. Intervention: BMR was measured by indirect calorimetry, under stringent, standardised conditions, for 20 min and on three different occasions in all patients. Continuous breath gas analysis using a mouthpiece was performed. Weight, height and skinfold measurements were performed before each measurement. Main outcome measures: BMR was expressed as percentage of the estimated reference value, according to the Scho®eld formulas based on age, weight and sex, and in kJ (kcal) per kg of fat-free mass. Results: At diagnosis, the BMR was higher than the estimated reference BMR in all patients and 44% of the patients were considered hypermetabolic. Mean BMR (as percentage of reference) was signi®cantly increased (11.6% (s.d. 6.7%); P 0.001), but decreased during treatment in 12 of the 13 patients (mean decrease 12.7% (s.d. 3.9%); P`0.0001). Furthermore, a signi®cant negative correlation (P À0.67; P 0.01) was found between the change in BMR and tumour response. Conclusions: These data suggest that the BMR of children with a solid tumour is increased at diagnosis and possibly during the ®rst phase of oncologic treatment. This may be important when determining energy requirements for nutritional support. Descriptors: child; solid tumour; basal metabolic rate; nutritional support; energy requirements
Introduction
A malignant tumour induces widespread changes in a child's metabolism, including their energy metabolism.
These changes, among which are an increased Cori-cycle, a failure to down-regulate energy expenditure in the presence of a reduced energy intake, and an increased lipolysis, lead to an ineffective use of nutrients (Yu, 1993; Kern & Norton, 1988; Picton, 1998; Pencharz, 1998; Andrassy & Chwals, 1998) . In addition, basal metabolic rate or resting energy expenditure may be increased as has been shown in several studies involving adult cancer patients (Kern & Norton, 1988; Fredrix et al, 1991a,b; Arbeit et al, 1984; Hyltander et al, 1993; Staal-van den Brekel et al, 1995; Bozetti et al, 1980; Lindmark et al, 1984; Luketich et al, 1990) . Aggravated by a reduced oral energy intake, this results in weight loss and a deterioration of nutritional status (Yu, 1993; Kern & Norton, 1988; Picton, 1998; Pencharz, 1998; Staal-van den Brekel et al, 1995) . Among the numerous negative implications of a poor nutritional status are a reduced tolerance to therapy, an increased infection rate, a decreased sense of well-being, and a decreased survival (Yu, 1993; Andrassy & Chwals, 1998; Lewinter-Suskind et al, 1993; Mauer et al, 1990; Rickard et al, 1986) . Nutritional support is, therefore, needed to increase energy intake, avert malnutrition and minimise the negative effects associated with weight loss.
Nutritional support programs should be tailored to the nutritional needs of each individual patient and should ensure an energy intake that results in a positive energy balance, enabling the child to grow and develop despite the presence of cancer (Picton, 1998; Pencharz, 1998; den Broeder et al, 1998 den Broeder et al, , 2000 . The general approach to estimating a child's total daily energy requirement in the absence of direct measurements is to add the energy associated with physical activity, thermogenesis and growth to the estimated basal metabolic rate (BMR), calculated according to the Scho®eld prediction equations (Scho®eld, 1985) . These equations have shown to provide accurate estimates of BMR in healthy children but not in children with various diseases and concomitant malnutrition (Picton, 1998; Firouzbaksh et al, 1993; Kaplan et al, 1995) . Therefore, when calculating total energy requirements in a clinical setting, the estimated BMR should also be corrected for the energy expenditure associated with the presence of disease (and concomitant malnutrition) in order to achieve a better estimate of the energy requirements. In contrast to adult cancer patients, however, data describing the effect of cancer on the BMR of children are limited and mainly involve children with acute lymphoblastic leukemia (Bond et al, 1992; Kien & Camitta, 1987; Vaisman et al, 1993; Stallings et al, 1989; Delbecque-Boussard et al, 1997) . The effect of the presence of a solid tumour on the BMR of children has not yet been evaluated and is therefore seldom corrected for. By measuring the BMR of a patient with a solid tumour, and comparing it with the estimated BMR according to Scho®eld of an individual with the same age, weight and sex, the in¯uence of the presence of a tumour on BMR can be determined, provided all other factors that may in¯uence BMR, such as fever and infection, are ruled out (Fredrix et al, 1991a,b) .
This study was set up to assess the level of BMR in children with a solid tumour at diagnosis and during treatment, in order to determine if, or by which factor, the estimated BMR, according to the Scho®eld equations, should be multiplied to correct for a tumour-induced change in BMR. This was done to obtain a more accurate estimate of a child's energy requirement for nutritional support in the absence of direct measurements. Furthermore, changes in BMR during the study period were assessed.
Patients and methods

Patients
Thirteen patients with a solid tumour (nine female and four male), recruited from a population of children visiting the Child's Oncology Centre of the University Hospital Nijmegen for treatment of their malignancy, were included in the study. Patients were included when they were older than 8.0 y, clinically stable, willing to participate and not diagnosed with acute lymphoblastic leukaemia. All patients asked to participate in the study took part in and completed the study. An informed consent was obtained from the parents of each patient and the Medical Ethics Committee of the University Hospital Nijmegen approved the study.
Patients were measured on three different occasions but as treatment protocols and condition of the patients varied, the time between two measurements was not the same for all patients. Before each measurement, the patient had to meet each of the following conditions, in order to exclude all factors other than the presence of the tumour that are known to in¯uence BMR (Pencharz, 1998; Fredrix et al, 1991a,b; Mauer et al, 1990) : (1) absence of fever (body temperature: 37 AE 1 C); (2) last chemotherapy (CT) course at least 2 weeks prior to the measurement; (3) no corticosteroids in the past week; (4) haemoglobin concentration b 6.0 mmolal; (5) surgery or radiotherapy (RT) occurred at least 4 (surgery) or 6 (RT) weeks prior to the measurement. It was assumed that after these periods a possible in¯uence on energy metabolism from the acute side effects associated with these therapeutic measures could be ignored (Brown, 1993; Kun, 1997; Fredrix et al, 1991a,b) ; (6) normal thyroid function.
Measurements of basal metabolic rate
BMR, de®ned as the minimum amount of energy required to maintain all essential bodily functions (Delbecque-Boussard et al, 1997), was determined by indirect calorimetry under standardised conditions, using a nose clip and a respiratory valve with rubber mouthpiece (Hans-Rudolph) held in place by a mechanical arm. The automatic gas analyser (Oxycon-4, Mijnhardt BV, Bunnik, The Netherlands) was calibrated before each measurement with certi®ed reference gas mixtures (Hoekloos BV, Dieren, The Netherlands), and was also regularly calibrated for volume.
All measurements were performed between 8.30 and 10.30 h after an overnight fast (12 ± 14 h), and room temperature was maintained at 22 ± 24 C. Each child rested for 10 min before the start of the measurement, and was given the opportunity to get acquainted with the mouth piece and nose clip. This was an important part of, especially, the initial measurement, as it has shown to minimise the measurement variability in children (Scott, 1993) . During the measurement, the child lay supine on a bed. The gas analysing system measured continuously over a period of 15 min and printouts were made at 1 min intervals, describing the mean values per minute (Firouzbakhsh et al, 1993) . The ®rst 5 min of each recording were discarded, since measured values have shown to be signi®cantly higher compared to a subsequent period of measurement (Isbell et al, 1991) , and to ensure a steady state (Warner et al, 1998; Firouzbakhsh et al, 1993) . Measurement error in the BMR in children with a solid tumour E den Broeder et al individual mean BMR, expressed as coef®cient of variation, was 3.7%. BMR was calculated by multiplying the oxygen consumption (in 1amin corrected to standard temperature and pressure, dry (STPD)), with the caloric equivalent per litre oxygen at the given steady-state respiratory quotient (RQ), and extrapolating data to a 24 h value (McArdle et al, 1996) . The RQ was assumed non-protein, since patients fasted in the preceding 12 ± 14 h. BMR was expressed in kJ (and kcal) per 24 h and in kJ (and kcal) per kg of fat-free mass (FFM) to correct for differences in body composition.
The BMR in kJ (kcal) per 24 h was expressed as percentage of the estimated value of BMR, calculated according to the Scho®eld formulas based on age, weight and sex (Scho®eld, 1985) . These formulas have been shown to provide accurate estimates of BMR in healthy children and are frequently used in the calculation of total energy requirements in the clinical setting (Firouzbakhsh et al, 1993; Kaplan et al, 1995) . These estimates, therefore, served as reference values. The BMR expressed as percentage of the reference value was used to assess whether the BMR of children with a solid tumour differed from the (estimated) BMR of healthy children due to the presence of a tumour, as all others factors possibly in¯uencing BMR were excluded. Patients with a BMR b 110% of the reference value were considered to be hypermetabolic (Boothby et al, 1936; Luketich et al, 1990) .
The BMR, expressed per kg of FFM, was used to assess intra-individual changes in BMR using each patient as his or her own control. The individual changes (as percentages) were subsequently correlated with changes in tumour response, which was scored by means of a ®ve point scoring system at every measurement (Do Èrfell et al, 1995) : complete remission 4, very good partial response (tumour decrease b 75%) 3, partial response (tumour decrease`75%) 2, no response 1, progressive disease (tumour increase b 25%) 0.
Anthropometrics
Weight, height and skinfold measurements (biceps, triceps, subscapular and suprailiacic skinfold) in threefold on the non-dominant arm, were performed by one observer, using standard techniques (Frisancho, 1981) . They were performed prior to each measurement of basal metabolic rate. Weight was expressed as percentage of standard weight for height (P50), according to reference values from Fredriks et al (2000) . FFM was determined from weight and the sum of the four skinfold measurements (Deurenberg et al, 1990) .
Data treatment
As diagnoses and corresponding treatment protocols varied, the number of days between two measurements was not the same for all patients. To provide information on the changes in BMR during treatment, the measurements were, therefore, grouped according to the phase of treatment in which they were taken. Phase 0, diagnosis; phase 1, after one or two courses of CT or after surgery; phase 2, after three or four courses of CT with or without surgery; and phase 3, after RT or after at least ®ve courses of CT. Regression analysis and appropriate t-tests were used to evaluate data. Spearman correlation coef®cients (r) were used to describe the association between tumour response and changes in BMR per kg FFM.
Results
Patient characteristics at time of ®rst measurement are summarised in Table 1 . Age ranged from 8.8 to 15.8 y and the types of tumours varied. The pubertal stage, indicated in Table 1 , did not change for any of the patients during the study period. Nine patients were measured at diagnosis and twice in follow-up, while the remaining four patients were measured on three different occasions during treatment but not at diagnosis (patients 10 ± 13). The average time interval between the ®rst and second, and the second and third measurement was 11 and 15 weeks, respectively.
Data on weight, height, skinfold thicknesses, body fat percentage and fat-free mass are shown in Table 2 . The weight of each patient before each measurement, expressed as percentage of the standard weight for height (P50), is also indicated. At the time of ®rst measurement, only one patient was classi®ed as poorly nourished (WFH`80% of reference) according to the classi®cation of Waterlow et al (1977) . Weight for height increased in six patients. In three of these patients, tube feeding was initiated at some point during the study period in order to increase energy intake (patients 6, 9 and 12). Tube feeding was also administered in patients 2 and 4. Weight for height remained stable or a Pre pre-pubertal; pub pubertal; post post-pubertal.
BMR in children with a solid tumour E den Broeder et al decreased during the study period in four out of 13 and three out of 13 patients, respectively. All measured basal metabolic rates, the corresponding reference values, and their differences (as percentages) are shown in Table 3 , as well as the phases of treatment in which the measurements were taken. Steady-state readings, following the initial 5 min of recording, were con®rmed in all patients and for all measurements. RQ values ranged from 0.72 to 0.98. The second measurement of patient 2 was excluded from analysis as the patient had a fever at time of measurement.
The distribution (Box plot) of the individual differences between the measured and reference BMR during each phase of treatment is presented in Figure 1 . Initially, a signi®cant difference with the reference value was observed (11.6% (s.d. 6.7%); paired t-test, P 0.001), while in phases 1, 2 and 3, a signi®cant difference was no longer observed. Figure 2 illustrates the effect of the presence of a tumour on the BMR of the individual patients during the different phases of treatment by indicating the difference between the measured and reference BMR, while other factors, which may possibly in¯uence BMR, are excluded. Only the patients measured at diagnosis were included (n 9) and patients were grouped according to the extent of the difference at ®rst measurement. The diagnosis of each Fredriks et al (2000) .
BMR in children with a solid tumour E den Broeder et al patient is also shown. The BMR at diagnosis ( phase 0) was higher than the reference value in all patients (range 3.0 ± 21.4%) and four were considered to be hypermetabolic, three of whom were diagnosed with a lymphoma. During treatment, the difference between the measured and reference BMR decreased in all patients indicating that the BMR of children with a solid tumour retumed to the values found in reference children. After one or two phases of treatment, none of the patients were considered hypermetabolic. In patient 3, BMR decreased considerably and the patient became hypometabolic (BMR`90% of reference value), but his thyroid function was normal. The measured BMRs of each patient, expressed in kJ (kcal) per kg of FFM, are also shown in Table 3 . Changes in BMR per kg FFM during treatment varied between patients, but a decrease between the ®rst and third measurement was observed in all patients measured at diagnosis (range À5.8 to À18.8%). A decrease of more than 10% was observed in seven of these patients, even when they were not initially considered hypermetabolic, and the mean Phase of treatment during which measurement was performed (0 before therapy; 1 after one or two courses of chemotherapy (CT) or surgery; 2 after three or four courses of CT; 3 after radiotherapy andaor more than four courses of chemotherapy). . b Measured basal metabolic rate ( 4.18* (VO 2 (1amin))* (kcalal O 2 )* 60* 24) (McArdle et al, 1996) . . c Reference basal metabolic rate (according to the Shof®eld formulas based on age, weight and sex)* 4.18 (Scho®eld, 1985) . . Basal metabolic rate per kg fat-free mass, calculated from weight and sum of four skinfolds according to Deurenberg et al (1990) . . f Excluded from analysis as patient had a fever at time of measurement.
BMR in children with a solid tumour E den Broeder et al decrease was signi®cant (12.7% (s.d. 3.9%); paired t-test, P`0.0001). In three of the four patients not measured at diagnosis, BMR per kg FFM also decreased, but the decrease was less pronounced, as was to be expected. BMR increased in one patient with recurrent disease (patient 10, 3.1%) and patient 13 was still hypermetabolic in phase 1 (Table 3) . His tumour did not respond well to the ®rst two courses to CT, in contrast to the third and fourth CT course.
Changes in BMR per kg FFM (as percentages), between the ®rst and second, second and third, and the ®rst and third measurement, were plotted against the corresponding changes in tumour response in Figure 3 , in order to determine whether the change in BMR was correlated with the change in tumour response. A signi®cant negative correlation was found between the change in BMR per kg FFM and the corresponding change in tumour response, between the ®rst and second and the ®rst and third measurement (r À0.66 (P 0.01); and r À0.67 (P 0.01), respectively).
Discussion
To our knowledge this is the ®rst study that longitudinally investigated the BMR of children with a solid tumour from Figure 2 The difference between the measured and reference BMR, during the different phases of treatment, for the nine patients measured at diagnosis. Patients are grouped according to the magnitude of the difference at diagnosis and the diagnosis of each patient is shown. Four patients were considered hypermetabolic at diagnosis as their BMR was more than 10% higher (dotted line) than the estimated reference BMR. Figure 1 Box-and-whisker plot of the individual differences with the BMR-reference value. The box is de®ned by the quartiles (P25, P50, P75) of the distribution. The whiskers extend to the extreme values. A signi®cant difference (P 0.001) between mean measured and reference value was found in phase 0 ( diagnosis). In the subsequent phases, the mean measured BMR was no longer signi®cantly different from the reference value.
BMR in children with a solid tumour E den Broeder et al diagnosis onwards. At diagnosis, the measured BMR was higher than the reference BMR in all patients (44% were considered hypermetabolic) and the mean increase was signi®cant (11.6%). During treatment, BMR per kg FFM decreased in all patients measured at diagnosis (mean decrease 12.6%) and after the ®rst two courses of CT the BMR of children with a solid tumour was no longer signi®cantly different from that of healthy reference children, calculated according to the Scho®eld formulas. The mouth pieceanose-clip system is not the most frequently used system to measure BMR in children. It is thought to result in hyperventilation or anxiety, which may lead to a signi®cant overestimation of BMR (Scott, 1993; Pencharz & Azcue, 1995) . A facemask or a ventilated canopy is, therefore, more often used. Isbell et al (1991) , however, have shown that not only the mouth pieceanoseclip system, but also the face mask and ventilated canopy, produce signi®cantly higher levels of resting energy expenditure (REE) { during the ®rst 5 min of measurement, which should, therefore, be discarded. In addition, they found no signi®cant differences in REE between data collected with each of these three systems, and that acceptable levels of reliability with the mouth pieceanose-clip system were obtained after a shorter measurement period (10 min following the 5 min acclimation period) compared to the ventilated canopy (20 min) and face mask (40 min) (Isbell et al, 1991) . Bearing this in mind, and the fact that only the mouth pieceanose-clip system was readily available to us, we chose to use this system in our study. As a consequence, only the older patients were included.
Younger children have shown not to tolerate a mouthpiece and nose-clip long enough to achieve a steady state, leading to an inaccurate assessment of energy expenditure (Picton, 1998) .
The increase in BMR, compared to the estimated BMR, found in all children at diagnosis indicates that the tumour is more than an inert mass requiring removal. It consists of metabolically active tissue that initially increases the child's basal energy requirements and which should, therefore, be taken into account when energy requirements for nutritional support are calculated. This changes during the course of treatment as can be concluded from our data. They show that the effect of the presence of a solid tumour on BMR reduced during treatment, when the tumour responded to therapy, as the difference between the measured and reference BMR decreased. After the ®rst (or second) phase of treatment, BMR was no longer signi®-cantly different from the reference BMR. Therefore, adjustment for increased energy demands imposed by the presence of a solid tumour after this period is no longer necessary, and the estimated BMR of a child with the same age, sex and weight as the patient can then be used in the calculation of energy requirements.
These data con®rm the ®ndings of studies, which investigated the metabolic rate in children with leukaemia from diagnosis onwards. Kien & Camitta (1987) and Stallings et al (1989) both measured increased metabolic rates at diagnosis in children with acute lymphoblastic leukaemia, but mainly in children with a high tumour burden. In response to treatment, the increase in metabolic rate disappeared within 14 days (Stallings et al, 1989) . The same observation was made by Merrit et al (1981) , who studied the BMR in children with acute non-lymphoblastic leukaemia. He found BMR to be raised over a period of 30 days after which values of BMR had returned to normal. In our
{
The general difference between REE and BMR are the conditions under which metabolic rate is measured. The conditions under which BMR is measured are usually more stringent, resulting in more accurate measurements and a decreased inter-and intra-individual variability. Figure 3 The change in BMR per kg FFM plotted against the change in tumour response between the ®rst and second, second and third, and ®rst and third measurement. Spearman correlation coef®cients (r) and P-values are indicated, of which the one between the ®rst and third measurement is the most relevant.
BMR in children with a solid tumour E den Broeder et al study it was dif®cult to comment on the exact time needed to`normalise' BMR. First of all, the time interval between two measurements was generally longer than 14 and 30 days, respectively, and was not the same for all patients. Furthermore, the decrease in BMR per kg of FFM was found to be associated with the response of the tumour to therapy and, thus, with the effectiveness of therapy. Since the effectiveness of therapy can vary considerably between patients and tumour types, it is not surprising that the time required to restore BMR was not the same for all patients. Our data, however, suggest that at least four courses of CT are needed to reduce the BMR of all patients with a solid tumour to`normal' levels, but that for most patients ( AE 70%) two courses of CT are suf®cient. This ®nding con®rms data from a study by Bond et al (1992) who found no increase in BMR in 10 children with different types of solid tumour on maintenance CT (more than three courses of CT in addition to initial diagnostic or therapeutic surgery).
The association between successful treatment, and a reduction in energy expenditure in patients with a raised basal energy expenditure at diagnosis, was also found in a study by Picton et al (1995) , who measured metabolic rate in both children with leukaemia and children with a solid tumour. The difference between our study and the study by Picton et al (1995) was that they measured sleeping metabolic rate, which is generally lower (7% (Fredrix et al, 1990) ) than BMR, in children who were considerably younger. The trend we found in our data, however, agrees with their results.
The extent of the metabolic strain that the presence of a tumour imposed on the individual varied and seemed to be tumour related, as three of the four hypermetabolic patients at diagnosis, were diagnosed with a lymphoma. The patient who was not measured at diagnosis, but who was still hypermetabolic in phase 1, was also diagnosed with a lymphoma. This relationship between tumour type and increased BMR has been seen earlier in studies with adult cancer patients (Fredrix et al, 1991a,b) .
The fact that BMR appears to be increased at diagnosis does not necessarily imply that the total energy requirements of children with a solid tumour are increased compared to the total energy requirements of healthy reference children. After all, the seemingly increased BMR at diagnosis is frequently accompanied by a decreased activity-induced energy expenditure (den Broeder et al, 2000) . The increased BMR merely indicates that the current calculation of total energy requirements underestimates actual requirements, especially at diagnosis, as the estimated BMR is not corrected for the increased energy demands induced by the presence of the tumour.
It must be noted that the sample size in this study was relatively small and that the group was fairly heterogeneous. Therefore, the group may not be representative for speci®c patient populations. The same problem was observed in the study by Bond et al (1992) who measured the BMR of 10 patients with various solid tumours on maintenance therapy. Apparently, in clinical research with a limited number of patients diagnosed with certain tumours, and a limited time frame, this can hardly be avoided. It must, therefore, always be kept in mind that different tumour types and stages may exert different effects on a patients' metabolism.
This study demonstrates that the BMR of children with a solid tumour is signi®cantly higher than the estimated reference BMR at diagnosis. In response to effective treatment, BMR reduces, also when the patient is not hypermetabolic, and the reduction is negatively correlated with tumour response. These results have implications for the current calculation of total energy requirements in children with a solid tumour. According to our study, the factor needed to correct for the tumour induced increase in BMR, is greater than 1.0 with a maximum of 1.21, at least until after the second course of CT. After this period no signi®cant difference with the estimated BMR of a healthy reference population is found.
